Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

Overcoming MCL-1-driven adaptive resistance to targeted therapies

(2020) Kris C. Wood   Nature Communications

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression

(2020) Yuto Yasuda et al.   Cell Death & Disease

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

(2020) Yonghan He et al.   Journal of Hematology & Oncology

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

(2020) Anna-Lena Scherr et al.   Cell Death & Disease

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

(2019) Erinna F. Lee et al.   Cell Death & Disease

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

(2019) Joan Montero et al.   Nature Communications

The Integrated Genomic Landscape of Thymic Epithelial Tumors

(2018) Milan Radovich et al.   CANCER CELL

Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition

(2018) Clare E. Weeden et al.   ONCOGENE

MCL-1 is a prognostic indicator and drug target in breast cancer

(2018) Kirsteen J. Campbell et al.   Cell Death & Disease

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity

(2018) Ryan S. Soderquist et al.   Nature Communications

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

(2018) Raphael Koch et al.   BLOOD

Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF-κB signalling

(2017) Djeda Belharazem et al.   Oncotarget

A Landscape of Pharmacogenomic Interactions in Cancer

(2016) Francesco Iorio et al.   CELL

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

(2015) Joan Montero et al.   CELL

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

(2015) Anish Thomas et al.   LANCET ONCOLOGY

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

(2015) A. N. Hata et al.   Cancer Discovery

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors

(2014) Iacopo Petrini et al.   NATURE GENETICS

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer

(2014) W Nakajima et al.   Cell Death & Disease

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

(2013) François Vaillant et al.   CANCER CELL

Corticomedullary differentiation and maturational arrest in thymomas

(2013) Philipp Ströbel et al.   HISTOPATHOLOGY

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas – Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c

(2013) Bei Huang et al.   Frontiers in Oncology

Establishment and characterization of a novel cell line derived from human thymoma AB tumor

(2012) Yesim Gökmen-Polar et al.   LABORATORY INVESTIGATION

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

(2012) Jan Budczies et al.   PLoS One

Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors

(2012) I Petrini et al.   Cell Death & Disease

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

(2011) A. A. Morales et al.   BLOOD

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL

Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience

(2010) P Ströbel et al.   BRITISH JOURNAL OF CANCER

A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma

(2010) Kenji Koga et al.   PATHOLOGY INTERNATIONAL

Thymic Carcinoma: Is it a Separate Entity? From Molecular to Clinical Evidence

(2010) Alexander Marx et al.   Thoracic Surgery Clinics

Chemotherapy for Thymic Tumors: Induction, Consolidation, Palliation

(2010) Arun Rajan et al.   Thoracic Surgery Clinics

Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma

(2008) Volker Ehemann et al.   INTERNATIONAL JOURNAL OF CANCER